Dr. Robert Allen, PhD - CSO, Invivyd - Protection From Serious Viral Infectious Diseases

Dr. Robert Allen, PhD is Chief Scientific Officer of Invivyd ( https://www.invivyd.com/ ), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2, by deploying a proprietary integrated technology platform, to create best in class monoclonal antibodies.

Dr. Allen brings over 30 years of experience across the infectious disease space, most recently as the Chief Scientific Officer of SmartPharm Therapeutics, a subsidiary of Sorrento Therapeutics. During that time, he led efforts to develop gene-encoded monoclonal antibodies for COVID-19 that could be quickly adapted to respond to emerging variants of concern. He also served concurrently as Senior Vice President, Antiviral and Oncolytic Immunotherapy Development, at Sorrento Therapeutics.

Prior to his time at SmartPharm Therapeutics, Dr. Allen held multiple senior scientific roles across the pharmaceutical and biotechnology industries including at Sorrento Therapeutics, SIGA Technologies, and the Oregon Translational Research and Development Institute.

Dr. Allen holds a Ph.D. in Microbiology from Columbia University, an M.S. in Applied Biology from Georgia Institute of Technology, and a B.S. in Biology from Rhodes College. He has published extensively in the field of virology and completed his postdoctoral training in virology at Washington University in St. Louis and Emory University.

#RobertAllen #Invivyd #Biopharmaceuticals #InfectiousDiseases #SARSCoV2 #MonoclonalAntibodies #Immunocompromised #RareViralEpitopes #Pemivibart #PreExposureProphylaxis #Covid19 #EmergencyUseAuthorization #EUA #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research